AustriaThe article discusses a legal dispute over the pricing transparency of Keytruda, the most expensive prescription drug in Austria. The issue centers around whether the price of this cancer medication, produced by pharmaceutical company MSD, should be made public. Multiple state administrative courts have issued conflicting rulings on the matter, with some refusing to disclose information while others partially complying. The Austrian Constitution Court (VfGH) has been involved as the case moves forward. MSD has challenged these decisions, arguing they violate new information rights for journalists and seeks to prevent the disclosure of procurement details related to the drug’s purchase by hospitals. The conflict highlights broader concerns about transparency in healthcare spending and the influence of pharmaceutical companies.
Lettura del bias (Centro): The article presents a balanced account of the legal battle involving multiple stakeholders—government agencies, hospitals, and the pharmaceutical company MSD. It reports on differing court rulings without overtly favoring any side, and avoids taking a clear ideological stance. While the issue is of
Perché questi punteggi (Fattualità 85 · Obiettività 75): The article accurately reports on the legal dispute over the pricing transparency of Keytruda, citing conflicting rulings from various state administrative courts. It provides context about the drug's cost and the pharmaceutical company's secrecy clauses. However, the tone leans slightly towards hig
